Compare Abbott Laboratories (ABT) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Valero Energy Corporation — how do they compare? Abbott Laboratories trades at $109.59 (market cap $187.95B), while Valero Energy Corporation trades at $325.95 (market cap $93.27B). The key difference: Abbott Laboratories is far larger — about 2× Valero Energy Corporation's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | VLO | |
|---|---|---|
Market Cap | $187.95B | $93.27B |
Sector | Health | Energy |
52-Week High | $136.62 | $323.92 |
52-Week Low | $82.57 | $133.38 |
Enterprise Value | $214.96B | $96.74B |
Dividend Yield | 2.32% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Valero Energy (VLO) trades at $314.95, up 5.58% in 24 hours, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $307 and resistance at $324. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $12.54 surpassing the $10.11 estimate. Revenue for 2026 is projected to rise to $139.4 billion, with net income margin improving to 5.17%.
Outlook remains positive due to robust refining margins and renewable diesel growth, but risks include volatile oil prices and geopolitical tensions. Analysts maintain a buy consensus with a $324.27 price target, indicating potential upside. Investors should monitor execution on earnings guidance and global energy supply dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
